Clinical Trials Logo

Pseudomonas Infections clinical trials

View clinical trials related to Pseudomonas Infections.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT00989807 Approved for marketing - Cystic Fibrosis Clinical Trials

Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis

EAP
Start date: n/a
Phase: N/A
Study type: Expanded Access

This program is to provide expanded access to aztreonam lysine for inhalation (AZLI) prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P. aeruginosa airway infection who have limited treatment options and are at risk for disease progression.

NCT ID: NCT00499720 Approved for marketing - Cystic Fibrosis Clinical Trials

Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection

Start date: n/a
Phase: N/A
Study type: Expanded Access

The primary objective of this program is to provide expanded access to aztreonam lysine for inhalation (AZLI) 75 mg prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P. aeruginosa airway infection who have limited treatment options and are at risk for disease progression.